Signs MOU With SCIINV

World Trade Center Genome Valley & Shamshabad entered into a Memorandum of Understanding (MoU with Hyderabad based SCIINV Biosciences, a digital diagnostic startup founded by women entrepreneurs, that will leverage the strengths in digital diagnostics to combat antimicrobial resistance (AMR). 

The collaboration will bring together SCIINV BioSciences’ network with academia and research organisations globally for scientific expertise in AMR and its proprietary digital diagnostic tool AMRx. 

The startup will also leverage wide network of World Trade Center - Shamshabad, India centres globally. The partnership is expected to help launch multiple digital diagnostic products for various bacterial infections in humans, animals and plants. 

Dr Uma Rani, CEO, SCI- INV Biosciences and Y Varaprasad Reddy, Chairman, World Trade Center, Shamshabad, India, signed the MoU, in the presence of Directors of SCIINV Bio- sciences, P Anasuya, P V Lakshmi and J Malathi. Chief Business officer of SCIINV. 

Biosciences B Krishna, Prof Pallu Reddanna, Executive President, Federation of Asian Biotech Associations, and Dr Ranga Reddy Burri, president of Infection Control Academy of India, also attended the event. 

Speaking on the occasion, Y Varaprasad Reddy said, “We are proud to partner with SCIINV Biosciences on this important mission against Antimicrobial Resistance”. He further added that World Trade Center with its wide network of centres globally will collaborate towards making healthcare accessible to wider masses through innovative diagnostics like AMRx. 

Dr Uma Rani explained that AMRx has been developed in collaboration with Sri Satya Sai Institute of Higher Learning (SSIHL). 

Speaking on the strategic alliance, Prof Reddanna said that this MoU can help in taking innovative diagnostic tools across markets globally, which can diagnose bacterial infections accurately while helping contain drug resistance across species. 

Commenting on the threat of AMR, Dr Ranga Reddy Burri said, “It is al- ready causing the death of millions worldwide. Without access to timely diagnostic results and sustainable antibiotic alternatives, antimicrobial stewardship efforts are ineffective. To combat AMR effectively, we must invest in technologies that can provide rapid diagnosis and promote the development of viable non-antibiotic treatments.”